---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-002348"
form_type: "8-K"
ticker: "BFRG"
cik: "0001829247"
company_name: "BullFrog AI Holdings, Inc."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:24:42.478227+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BullFrog AI receives Australian patent for mebendazole prodrugs including BF-223

## Summary
- Australian Patent No. 2019216757 issued for novel prodrugs of mebendazole to treat cancers.
- Follows U.S. Patent No. 11,712,435 issued July 2023; additional territories expected.
- Patented compounds show improved solubility and oral bioavailability versus parent mebendazole.
- BF-223, a key pipeline asset, previously showed anticancer activity in a glioblastoma animal model.
- CEO Vin Singh says patent strengthens IP protection and supports partnering strategy.

## SEC filing metadata
- accession: 0001493152-24-002348
- form_type: 8-K
- ticker: BFRG
- cik: 0001829247
- company_name: BullFrog AI Holdings, Inc.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829247/000149315224002348/0001493152-24-002348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829247/000149315224002348/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-002348
- JSON: https://secwatch.observer/filing/0001493152-24-002348.json
- Plain text: https://secwatch.observer/filing/0001493152-24-002348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.